Targeting heterogeneous depression with trazodone prolonged release: from neuropharmacology to clinical application.

IF 3.6 3区医学 Q1 PSYCHIATRY

Annals of General Psychiatry Pub Date : 2025-05-22 DOI:10.1186/s12991-025-00563-z

Andrea Fagiolini, Lea Dolenc Grošelj, Marina Šagud, Ante Silić, Milan Latas, Čedo D Miljević, Alessandro Cuomo

{"title":"Targeting heterogeneous depression with trazodone prolonged release: from neuropharmacology to clinical application.","authors":"Andrea Fagiolini, Lea Dolenc Grošelj, Marina Šagud, Ante Silić, Milan Latas, Čedo D Miljević, Alessandro Cuomo","doi":"10.1186/s12991-025-00563-z","DOIUrl":null,"url":null,"abstract":"Aim: This paper evaluates the clinical efficacy, safety, and practical implications of Trazodone Prolonged Release (PR) in managing depression, anxiety, and sleep disorders, with a focus on its multimodal mechanism of action and advantages over traditional therapies.Methodology: A critical review of recent literature (2020-2024) [1-3] was conducted, analyzing data from clinical trials, real-world studies, and European treatment guidelines to assess the pharmacodynamics, pharmacokinetics, and therapeutic outcomes of Trazodone PR.Results: Trazodone PR demonstrates efficacy in addressing complex symptoms of depression, anxiety, and sleep disturbances, with a favorable safety profile and reduced risk of sexual dysfunction and weight gain compared to other antidepressants. Its ability to modulate serotonin, norepinephrine, dopamine, and histamine systems enhances mood, sleep quality, and cognitive recovery.Conclusion: Trazodone PR is a versatile and well-tolerated treatment option for patients with comorbid conditions and treatment-resistant cases. Its multimodal action, combined with benefits like improved neuroplasticity through BDNF production, makes it a suitable choice for the long-term management of mood disorders and associated conditions [4-6].","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"24 1","pages":"31"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096638/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-025-00563-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This paper evaluates the clinical efficacy, safety, and practical implications of Trazodone Prolonged Release (PR) in managing depression, anxiety, and sleep disorders, with a focus on its multimodal mechanism of action and advantages over traditional therapies.

Methodology: A critical review of recent literature (2020-2024) [1-3] was conducted, analyzing data from clinical trials, real-world studies, and European treatment guidelines to assess the pharmacodynamics, pharmacokinetics, and therapeutic outcomes of Trazodone PR.

Results: Trazodone PR demonstrates efficacy in addressing complex symptoms of depression, anxiety, and sleep disturbances, with a favorable safety profile and reduced risk of sexual dysfunction and weight gain compared to other antidepressants. Its ability to modulate serotonin, norepinephrine, dopamine, and histamine systems enhances mood, sleep quality, and cognitive recovery.

Conclusion: Trazodone PR is a versatile and well-tolerated treatment option for patients with comorbid conditions and treatment-resistant cases. Its multimodal action, combined with benefits like improved neuroplasticity through BDNF production, makes it a suitable choice for the long-term management of mood disorders and associated conditions [4-6].

查看原文本刊更多论文

曲唑酮缓释治疗异质性抑郁症：从神经药理学到临床应用。

目的：评价曲唑酮缓释（PR）治疗抑郁、焦虑和睡眠障碍的临床疗效、安全性和实际意义，重点介绍其多模式作用机制及其相对于传统疗法的优势。方法：对近期文献（2020-2024）[1-3]进行了批判性回顾，分析了来自临床试验、现实世界研究和欧洲治疗指南的数据，以评估曲唑酮pr的药效学、药代动力学和治疗结果。曲唑酮PR在治疗抑郁、焦虑和睡眠障碍的复杂症状方面显示出疗效，与其他抗抑郁药相比，具有良好的安全性，降低了性功能障碍和体重增加的风险。它调节血清素、去甲肾上腺素、多巴胺和组胺系统的能力增强了情绪、睡眠质量和认知恢复。结论：曲唑酮PR是一种多用途且耐受性良好的治疗选择，适用于有合并症和治疗耐药的患者。它的多模态作用，加上通过BDNF产生改善神经可塑性等益处，使其成为长期治疗情绪障碍和相关疾病的合适选择[4-6]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of General Psychiatry PSYCHIATRY-

CiteScore

6.60

自引率

2.70%

发文量

审稿时长

>12 weeks

期刊介绍： Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.